α-Lipoic acid as a new treatment option for Alzheimer’s disease — a 48 months follow-up analysis (original) (raw)

Abstract

Oxidative stress and neuronal energy depletion are characteristic biochemical hallmarks of Alzheimer’s disease (AD). It is therefore conceivable that pro-energetic and antioxidant drags such as α-lipoic acid might delay the onset or slow down the progression of the disease. In a previous study, 600 mg α-lipoic acid was given daily to nine patients with AD (receiving a standard treatment with choline-esterase inhibitors) in an open-label study over an observation period of 12 months. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (the mini mental state exam, MMSE and the Alzheimer’s disease assessment score cognitive subscale, ADAScog). In this report, we have extended the analysis to 43 patients over an observation period of up to 48 months. In patients with mild dementia (ADAScog < 15), the disease progressed extremely slowly (ADAScog: +1.2 points/year, MMSE:-0.6 points/year), in patients with moderate dementia at approximately twice the rate. However, the progression appears dramatically lower than data reported for untreated patients or patients on choline-esterase inhibitors in the second year of long-term studies. Despite the fact that this study was not double-blinded, placebo-controlled and randomized, our data suggest that treatment with α-lipoic acid might be a successful ‘neuroprotective’ therapy option for AD. However, a state-of-the-art phase II trial is needed urgently.

Preview

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

• AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115
  Article Google Scholar
• Biewenga GP, Haenen GR, Bast A (1997) The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 29: 315–331
  PubMed CAS Google Scholar
• Farlow MR, Lilly ML, Group EBS (2005) Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 years. BMC Geriatrics 5: 3
  Article PubMed Google Scholar
• Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ (1997) A multicenter evaluation of new treatment efficacy instruments for Alzheimer’s disease clinical trials, overview and general results. Alzheimer Dis Assoc Disord 11: S1–S12
  Article PubMed Google Scholar
• Frölich L, Riederer P (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneimittelforschung 45: 443–446
  PubMed Google Scholar
• Galasko DR, Gould RL, Abramson IS, Salmon DP (2000) Measuring cognitive change in a cohort of patients with Alzheimer’s disease. Stat Med 19: 1421–1432
  Article PubMed CAS Google Scholar
• Götz ME, Kunig G, Riederer P, Youdim MB (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37–122
  Article PubMed Google Scholar
• Hager K, Marahrens A, Kenklies M, Riederer P, Münch G (2001) Alphalipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 32: 275–282
  Article PubMed CAS Google Scholar
• Han L, Cole M, Bellavance F, McCusker J, Primeau F (2000) Tracking cognitive decline in Alzheimer’s disease using the Mini-Mental State examination: a meta-analysis. Int Psychogeriatr 12: 231–247
  Article PubMed CAS Google Scholar
• Haxby JV, Raffaele K, Gillette J, Schapiro MB, Rapoport SI (1992) Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type. J Clin Exp Neuropsychol 14: 575–592
  PubMed CAS Google Scholar
• Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Munch G (2006) Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias. Pharmacol Ther 113: 154–164
  Article PubMed Google Scholar
• Mohs RC (1996) Comprehensive and neuropsychologic evaluations: the Alzheimer’s disease assessment scale. Int Psychogeriatr 8: 195–203
  Article PubMed CAS Google Scholar
• Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P (1998) Alzheimer’s disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105: 439–461
  Article PubMed Google Scholar
• Packer L, Witt EH, Tritschler HJ (1995) alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227–250
  Article PubMed CAS Google Scholar
• Perry G, Castellani RJ, Hirai K, Smith MA (1998) Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis 1: 45–55
  PubMed CAS Google Scholar
• Rascovsky K, Salmon DP, et al. (2005) Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 65: 397–403
  Article PubMed CAS Google Scholar
• Retz W, Gsell W, Münch G, Rösier M, Riederer P (1998) Free radicals in Alzheimer’s disease. J Neural Transm Suppl 54: 221–236
  PubMed CAS Google Scholar
• Rösier M, Retz W, Thome J, Riederer P (1998) Free radicals in Alzheimer’s dementia: currently available therapeutic strategies. J Neural Transm Suppl 54: 211–219
  Google Scholar
• Stern R, Mohs R, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E (1994) A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151: 390–396
  PubMed CAS Google Scholar
• Storey E, Slavin MJ, Kinsella GJ (2002) Patterns of cognitive impairment in Alzheimer’s disease: assessment and differential diagnosis. Front Biosci 7: el55–el84
  Article Google Scholar
• Van Gool AW, Weinstein HC, Scheltens P, Walstra GJ (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 358: 455–460
  Article PubMed Google Scholar
• Winblad B, Engedal K, et al. (2001) A 1-year, randomized, placebocontrolled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495
  PubMed CAS Google Scholar
• Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, Schinzel R, Wiesinger H, Riederer P, Münch G (2001) Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci 14: 1961–1967
  Article PubMed CAS Google Scholar

Download references

Author information

Authors and Affiliations

1. Department of Medical Rehabilitation and Geriatrics, Henriettenstiftung, Hannover, Germany
   K. Hager & M. Kenklies
2. Zentaris GmbH, Frankfurt am Main, Germany
   J. Engel
3. Comparative Genomics Centre, Department of Biochemistry and Molecular Biology, James Cook University, Molecular Sciences Building 21, Townsville, 4811, Australia
   J. McAfoose & Dr. G. Münch

Authors

1. K. Hager
   You can also search for this author inPubMed Google Scholar
2. M. Kenklies
   You can also search for this author inPubMed Google Scholar
3. J. McAfoose
   You can also search for this author inPubMed Google Scholar
4. J. Engel
   You can also search for this author inPubMed Google Scholar
5. Dr. G. Münch
   You can also search for this author inPubMed Google Scholar

Editor information

Editors and Affiliations

1. Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Würzburg, Germany
   M. Gerlach
2. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Germany
   Jürgen Deckert
3. Prince of Wales Medical Research Institute, Sydney, Australia
   K. Double
4. Institut für Virologie und Immunobiologie, Würzburg, Germany
   E. Koutsilieri

Rights and permissions

Copyright information

© 2007 Springer-Verlag

About this paper

Cite this paper

Hager, K., Kenklies, M., McAfoose, J., Engel, J., Münch, G. (2007). α-Lipoic acid as a new treatment option for Alzheimer’s disease — a 48 months follow-up analysis. In: Gerlach, M., Deckert, J., Double, K., Koutsilieri, E. (eds) Neuropsychiatric Disorders An Integrative Approach. Journal of Neural Transmission. Supplementa, vol 72. Springer, Vienna. https://doi.org/10.1007/978-3-211-73574-9\_24

Download citation

• .RIS
• .ENW
• .BIB
• DOI: https://doi.org/10.1007/978-3-211-73574-9\_24
• Publisher Name: Springer, Vienna
• Print ISBN: 978-3-211-73573-2
• Online ISBN: 978-3-211-73574-9
• eBook Packages: MedicineMedicine (R0)

Publish with us